Glucose control using a closed-loop device decreases inflammation after cardiovascular surgery without increasing...

Area of Science:

• Cardiovascular Surgery
• Intensive Care Medicine
• Metabolic Regulation

Background:

• Tight glucose control may mitigate inflammation post-cardiac surgery.
• The efficacy of a 110-180 mg/dL glucose target range for controlling inflammation remains uncertain.

Purpose of the Study:

• To investigate if a glucose target range of 110-180 mg/dL decreases inflammation following cardiovascular surgery.
• To compare the inflammatory response between closed-loop and conventional glucose control methods.

Main Methods:

• Retrospective study of 72 cardiovascular surgery patients.
• Two groups: closed-loop control (110-180 mg/dL) vs. conventional control (<200 mg/dL).
• Primary outcome: C-reactive protein (CRP) levels on postoperative days 1, 2, and 7.

Main Results:

• The closed-loop group exhibited significantly lower average glucose levels (169±24 vs. 201±36 mg/dL) and glucose variability (22±13 vs. 44±20 mg/dL).
• Significantly lower CRP levels were observed in the closed-loop group on postoperative days 2 (10.8±5.6 vs. 14.1±5.7 mg/dL) and 7 (4.6±2.5 vs. 7.3±4.0 mg/dL).

Conclusions:

• Glucose control using a closed-loop device within the 110-180 mg/dL range may reduce post-cardiovascular surgery inflammation.
• This method appears effective without elevating the risk of hypoglycemia.